Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

There is currently no known cure for dementia, as Xu notes. But up to half of all dementia cases might be preventable, and scientists have identified over a dozen modifiable risk factors that ...

In a nutshell People with type 2 diabetes taking semaglutide (Ozempic/Wegovy) showed up to 46% lower dementia risk compared to those on other diabetes medications The protective effects were ...

A new study from Case Western Reserve School of Medicine suggests that GLP-1 weight loss drugs like Ozempic and Wegovy could lower your risk of developing dementia.

The unexpected ways Ozempic-like drugs might fight dementia. They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...

Researchers at Case Western Reserve University have discovered that the popular diabetes and weight-loss drug Ozempic may lower a person’s risk of developing dementia.. The active ingredient in ...

Results from this study show that there is a direct correlation between the use of anti-obesity medications and testosterone levels,” the study author said.

Talk about a lucky charm. Drugs like Ozempic — which mimic the appetite-suppressing GLP-1 hormone the body naturally produces after eating — have been shown to spur weight loss as well as ease ...

A new study involving nearly 1.7 million patients suggests that semaglutide — a drug that mimics a gut hormone to lower blood sugar and aid weight loss — could significantly cut dementia risk ...

Weight loss drug Ozempic may also reduce the risk of dementia, suggests a new study. American researchers found that semaglutide - the active ingredient in Ozempic and another weight loss ...

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves once each week. In newly released clinical trial data, Amgen’s once ...